<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lung Cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-hlt</span>
</mark>
 Screening Eligibility and Utilization Among 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transgender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 Patients: An Analysis of the 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    2017–2018
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-tme</span>
</mark>
 
<mark class="entity" style="background: #ff2600; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    United States
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-loc</span>
</mark>
 
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Behavioral Risk Factor Surveillance System
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-dat</span>
</mark>
 
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Survey
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-mth</span>
</mark>
. Introduction 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transgender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 and 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 diverse (TGD) persons disproportionately face many health disparities including a higher 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    risk
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-pcp</span>
</mark>
 of 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lung cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-hlt</span>
</mark>
. 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Lung cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-hlt</span>
</mark>
 screening (LCS) using low-
<mark class="entity" style="background: lightyellow; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dose
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">P-reg</span>
</mark>
 chest computed tomography has reduced 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lung cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-hlt</span>
</mark>
 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mortality
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-hlt</span>
</mark>
 in eligible high-
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    risk
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-pcp</span>
</mark>
 smokers across several large trials, yet utilization of LCS remains low. TGD persons may be 
<mark class="entity" style="background: #62d835; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    less likely to
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">R-rel</span>
</mark>
 receive recommended 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-hlt</span>
</mark>
 screening compared with 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cisgender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 populations. We sought to compare eligibility for and utilization of LCS between TGD and 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cisgender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 persons in the 
<mark class="entity" style="background: #ff2600; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    United States
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-loc</span>
</mark>
. We also examined if the utilization of LCS varied by 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    smoking status
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-use</span>
</mark>
 within each 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 identity group. Methods We analyzed data from the 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    2017
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-tme</span>
</mark>
 and 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    2018
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-tme</span>
</mark>
 
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Behavioral Risk Factor Surveillance System
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-dat</span>
</mark>
 (
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BRFSS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-dat</span>
</mark>
) 
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cross-sectional survey
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-mth</span>
</mark>
 to determine eligibility and utilization of LCS among TGD participants compared with 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cisgender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 persons. Logistical regression analysis of potentially 
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confounding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-mth</span>
</mark>
 variables included 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    age
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-age</span>
</mark>
 category, 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    race/ethnicity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-rac</span>
</mark>
, income, employment status, health insurance, and having a personal doctor. Results Of 37 023 weighted 
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respondents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-mth</span>
</mark>
, 0.5% were TGD. Although eligibility for LCS was statistically similar (8.8% TGD vs. 12.2% 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cisgender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
) (
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adjusted odds ratio
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-sts</span>
</mark>
 = 0.81, 
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    95% confidence interval
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-sts</span>
</mark>
 = 0.27–2.39, p = .703), only 2.3% of TGD participants reported obtaining a LCS chest computed tomography versus 17.2% of 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cisgender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 participants (
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adjusted odds ratio
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-sts</span>
</mark>
 = 0.04, 
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    95% confidence interval
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-sts</span>
</mark>
 = 0.01–0.59, p = .019). 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Smoking status
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-use</span>
</mark>
 showed no 
<mark class="entity" style="background: #57db94; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    association
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">M-sts</span>
</mark>
 with LCS utilization among 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 identity groups. Conclusions TGD persons may be 
<mark class="entity" style="background: #62d835; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    less likely to
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">R-rel</span>
</mark>
 receive LCS despite having similar 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    smoking status
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-use</span>
</mark>
 and eligibility of 
<mark class="entity" style="background: lightblue; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cisgender
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">D-gen</span>
</mark>
 persons, suggesting a disparity in utilization of this preventative health service. Implications Targeted efforts to increase LCS utilization and promote 
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    smoking cessation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ces</span>
</mark>
 for at-
<mark class="entity" style="background: #b9db57; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    risk
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-pcp</span>
</mark>
 TGD patients may be warranted.nan</div>